vs
Cytek Biosciences, Inc.（CTKB）与HARVARD BIOSCIENCE INC（HBIO）财务数据对比。点击上方公司名可切换其他公司
Cytek Biosciences, Inc.的季度营收约是HARVARD BIOSCIENCE INC的2.6倍（$62.1M vs $23.7M）。HARVARD BIOSCIENCE INC净利率更高（-12.0% vs -70.9%，领先58.9%）。Cytek Biosciences, Inc.同比增速更快（8.1% vs -3.3%）。HARVARD BIOSCIENCE INC自由现金流更多（$-545.0K vs $-1.8M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs -1.6%）
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
CTKB vs HBIO — 直观对比
营收规模更大
CTKB
是对方的2.6倍
$23.7M
营收增速更快
CTKB
高出11.5%
-3.3%
净利率更高
HBIO
高出58.9%
-70.9%
自由现金流更多
HBIO
多$1.2M
$-1.8M
两年增速更快
CTKB
近两年复合增速
-1.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $62.1M | $23.7M |
| 净利润 | $-44.1M | $-2.8M |
| 毛利率 | 52.9% | 59.7% |
| 营业利润率 | -9.0% | 7.2% |
| 净利率 | -70.9% | -12.0% |
| 营收同比 | 8.1% | -3.3% |
| 净利润同比 | -557.1% | -15916.7% |
| 每股收益（稀释后） | — | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTKBHBIO
| Q4 25 | $62.1M | $23.7M | ||
| Q3 25 | $52.3M | $20.6M | ||
| Q2 25 | $45.6M | $20.4M | ||
| Q1 25 | $41.5M | $21.8M | ||
| Q4 24 | $57.5M | $24.6M | ||
| Q3 24 | $51.5M | $22.0M | ||
| Q2 24 | $46.6M | $23.1M | ||
| Q1 24 | $44.9M | $24.5M |
净利润CTKBHBIO
| Q4 25 | $-44.1M | $-2.8M | ||
| Q3 25 | $-5.5M | $-1.2M | ||
| Q2 25 | $-5.6M | $-2.3M | ||
| Q1 25 | $-11.4M | $-50.3M | ||
| Q4 24 | $9.6M | $18.0K | ||
| Q3 24 | $941.0K | $-4.8M | ||
| Q2 24 | $-10.4M | $-2.9M | ||
| Q1 24 | $-6.2M | $-4.7M |
毛利率CTKBHBIO
| Q4 25 | 52.9% | 59.7% | ||
| Q3 25 | 52.7% | 58.4% | ||
| Q2 25 | 52.3% | 56.4% | ||
| Q1 25 | 48.6% | 56.0% | ||
| Q4 24 | 58.5% | 57.1% | ||
| Q3 24 | 56.3% | 58.1% | ||
| Q2 24 | 54.6% | 57.2% | ||
| Q1 24 | 51.3% | 60.3% |
营业利润率CTKBHBIO
| Q4 25 | -9.0% | 7.2% | ||
| Q3 25 | -17.6% | 1.0% | ||
| Q2 25 | -23.3% | -4.0% | ||
| Q1 25 | -36.1% | -228.1% | ||
| Q4 24 | 5.2% | 0.0% | ||
| Q3 24 | -8.2% | -8.5% | ||
| Q2 24 | -18.3% | -9.0% | ||
| Q1 24 | -23.9% | -9.3% |
净利率CTKBHBIO
| Q4 25 | -70.9% | -12.0% | ||
| Q3 25 | -10.5% | -6.0% | ||
| Q2 25 | -12.2% | -11.2% | ||
| Q1 25 | -27.5% | -231.2% | ||
| Q4 24 | 16.8% | 0.1% | ||
| Q3 24 | 1.8% | -21.9% | ||
| Q2 24 | -22.4% | -12.7% | ||
| Q1 24 | -13.8% | -19.1% |
每股收益（稀释后）CTKBHBIO
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-1.14 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | — | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.9M | $8.6M |
| 总债务越低越好 | — | $35.9M |
| 股东权益账面价值 | $341.7M | $13.7M |
| 总资产 | $461.5M | $80.1M |
| 负债/权益比越低杠杆越低 | — | 2.61× |
8季度趋势，按日历期对齐
现金及短期投资CTKBHBIO
| Q4 25 | $90.9M | $8.6M | ||
| Q3 25 | $93.3M | $6.8M | ||
| Q2 25 | $75.5M | $7.4M | ||
| Q1 25 | $95.3M | $5.5M | ||
| Q4 24 | $98.7M | $4.1M | ||
| Q3 24 | $162.3M | $4.6M | ||
| Q2 24 | $177.9M | $4.0M | ||
| Q1 24 | $168.8M | $4.3M |
总债务CTKBHBIO
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
股东权益CTKBHBIO
| Q4 25 | $341.7M | $13.7M | ||
| Q3 25 | $378.6M | $14.1M | ||
| Q2 25 | $377.6M | $15.7M | ||
| Q1 25 | $379.6M | $14.8M | ||
| Q4 24 | $395.7M | $63.3M | ||
| Q3 24 | $385.5M | $65.3M | ||
| Q2 24 | $389.1M | $67.2M | ||
| Q1 24 | $392.6M | $68.8M |
总资产CTKBHBIO
| Q4 25 | $461.5M | $80.1M | ||
| Q3 25 | $494.9M | $78.0M | ||
| Q2 25 | $493.3M | $80.1M | ||
| Q1 25 | $482.6M | $79.8M | ||
| Q4 24 | $499.5M | $126.6M | ||
| Q3 24 | $491.2M | $131.2M | ||
| Q2 24 | $483.7M | $128.9M | ||
| Q1 24 | $492.1M | $133.2M |
负债/权益比CTKBHBIO
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-771.0K | $-96.0K |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-545.0K |
| 自由现金流率自由现金流/营收 | -2.9% | -2.3% |
| 资本支出强度资本支出/营收 | 1.6% | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.8M | $5.5M |
8季度趋势，按日历期对齐
经营现金流CTKBHBIO
| Q4 25 | $-771.0K | $-96.0K | ||
| Q3 25 | $-3.9M | $1.1M | ||
| Q2 25 | $108.0K | $2.8M | ||
| Q1 25 | $-125.0K | $3.0M | ||
| Q4 24 | $2.0M | $1.7M | ||
| Q3 24 | $13.2M | $-842.0K | ||
| Q2 24 | $6.2M | $-846.0K | ||
| Q1 24 | $4.0M | $1.4M |
自由现金流CTKBHBIO
| Q4 25 | $-1.8M | $-545.0K | ||
| Q3 25 | $-4.6M | $877.0K | ||
| Q2 25 | $-1.5M | $2.7M | ||
| Q1 25 | $-974.0K | $2.5M | ||
| Q4 24 | $1.1M | $1.4M | ||
| Q3 24 | $12.2M | $-1.7M | ||
| Q2 24 | $5.2M | $-1.7M | ||
| Q1 24 | $3.4M | $758.0K |
自由现金流率CTKBHBIO
| Q4 25 | -2.9% | -2.3% | ||
| Q3 25 | -8.7% | 4.3% | ||
| Q2 25 | -3.2% | 13.0% | ||
| Q1 25 | -2.3% | 11.4% | ||
| Q4 24 | 1.9% | 5.8% | ||
| Q3 24 | 23.7% | -7.8% | ||
| Q2 24 | 11.0% | -7.2% | ||
| Q1 24 | 7.6% | 3.1% |
资本支出强度CTKBHBIO
| Q4 25 | 1.6% | 1.9% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 3.5% | 0.4% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 2.0% | 4.0% | ||
| Q2 24 | 2.3% | 3.5% | ||
| Q1 24 | 1.3% | 2.6% |
现金转化率CTKBHBIO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 95.83× | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
